Status:
RECRUITING
68Ga-P16-093 and 68Ga-PSMA-11 PET/CT Imaging in the Same Group of Primary Prostate Cancer Patients
Lead Sponsor:
Peking Union Medical College Hospital
Conditions:
Prostate Cancer
Eligibility:
MALE
18-90 years
Phase:
NA
Brief Summary
Prostate-specific membrane antigen (PSMA)-targeted PET imaging with 68Ga-labeled compounds is able to provide superior sensitivity and specificity to detect primary prostate tumor and its metastases, ...
Detailed Description
Prostate cancer (PC) is one of the most common malignancies worldwide in men, with persistently high numbers dying from this disease. Due to low levels of glycolysis in prostate cancer cell, the uses ...
Eligibility Criteria
Inclusion
- histologically confirmed untreated primary prostate cancer patients;
- 68Ga-PSMA-11 and 68Ga-P16-093 PET/CT within a week;
- signed written consent.
Exclusion
- known allergy against PSMA;
- any medical condition that in the opinion of the investigator may significantly interfere with study compliance.
Key Trial Info
Start Date :
April 15 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT05324332
Start Date
April 15 2022
End Date
December 31 2025
Last Update
September 22 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China, 100730